Description
LCL-161 is under investigation for its potential role in the treatment of colorectal cancer (CRC) by targeting the Wnt pathway. It has shown efficacy in preclinical models but clinical data are limited and it is not yet approved or widely used for CRC treatment.
Mechanism of Action
LCL-161 is an orally bioavailable small molecule that inhibits the Wnt/ -catenin signaling pathway by binding to and stabilizing Axin, a key component of the destruction complex.
Side Effects
Nausea; Diarrhea; Fatigue
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02890069
med_phase_prefix1
Archived
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
United States, Germany, Netherlands, South Korea, Spain, Taiwan, United Kingdom
Quick Info
| Category | Other Medications |
 Estado EMA | med_ema_not_submitted |
 Acceso España | med_spain_not_available |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.